Phase I study of oral suberoylanilide hydroxamic acid (SAHA) in patients (pts) with advanced leukemias or myelodysplastic syndromes (MDS).

被引：0
|
作者：
Garcia-Manero, G
Canalli, AA
Wierda, W
Cortes, J
O'Brien, S
Cupo, A
Secrist, JP
Davis, J
Faderl, S
Giles, F
Chiao, JH
Richon, V
Issa, JP
Kantarjian, H
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Aton Pharma, Tarrytown, NY USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4742
引用
收藏
页码：254B / 254B
页数：1
相关论文
共 50 条
  • [21] Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphomas
    Talpur, R
    Chiao, N
    Richon, V
    Chiao, JH
    Duvic, M
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 122 (03) : A53 - A53
  • [22] Phase I study of vorinostat (suberoylanilide hydroxamic acid [SAHA]) in combination with temozolomide in patients with malignant gliomas (NABTC 04-03)
    Wen, Patrick
    Puduvalli, Vinay
    Kuhn, John
    Reid, Joel
    Cloughesy, Timothy
    Yung, Wka
    Drappatz, Jan
    Lamborn, Kathleen
    Gilbert, Mark
    Butowski, Nicholas
    Levin, Victor
    Chang, Susan
    Kesari, Santosh
    Robbins, Hi
    McGovern, Renee
    Richon, Victoria
    Frankel, Stanley
    Ames, Matthew
    Zweibel, James
    Prados, Michael
    NEURO-ONCOLOGY, 2007, 9 (04) : 518 - 518
  • [23] NCI 6896: A phase I trial of suberoylanilide hydroxamic acid (SAHA) and 13-cis retinoic acid in the treatment of patients with advanced renal cell carcinoma
    Nanus, D. M.
    Tagawa, S. T.
    Dutcher, J. P.
    Akhtar, N. H.
    Saran, A.
    Mazumdar, M.
    Milowsky, M. I.
    Gudas, L. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [24] Phase I clinical trial of oral administration of the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with relapsed/refractory multiple myeloma
    Richardson, P
    Schlossman, RL
    Mitsiades, CS
    Munshi, NC
    Colson, K
    Doss, D
    McKenney, M
    Hande, K
    Gorelik, S
    Lunde, L
    Stepanek, A
    Freeman, A
    Dinand, K
    Hayes, S
    Michelle, R
    Doucet, K
    Warren, D
    Mitsiades, N
    Richon, VM
    Chiao, J
    Anderson, KC
    BLOOD, 2004, 104 (11) : 420A - 420A
  • [25] A phase II study of suberoylanilide hydroxamic acid (SAHA) in subjects with locally advanced, recurrent, or metastatic adenoid cystic carcinoma (ACC)
    Goncalves, Priscila Hermont
    Kummar, Shivaani
    Siu, Lillian L.
    Hansen, Aaron Richard
    Savvides, Panayiotis
    Sukari, Ammar
    Chao, Joseph
    Heilbrun, Lance K.
    Pilat, Mary Jo
    Smith, Daryn W.
    Casetta, Lindsay
    Boerner, Scott Anthony
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] RESULTS FROM PHASE I/II STUDY OF THE COMBINATION OF ORAL RIGOSERTIB AND AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
    Navada, S.
    Garcia-Manero, G.
    Hearn, K.
    Odchimar-Reissig, R.
    Demakos, E.
    Alvarado, Y.
    Daver, N.
    DiNardo, C.
    Konopleva, M.
    Borthakur, G.
    Fenaux, P.
    Fruchtman, S.
    Zbyszewski, P.
    Silverman, L.
    HAEMATOLOGICA, 2016, 101 : 74 - 74
  • [27] A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)
    Navada, Shyamala C.
    Silverman, Lewis R.
    Hearn, Katherine P.
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney
    Konopleva, Marina
    Borthakur, Gautam
    Pemmaraju, Naveen
    Kadia, Tapan
    Fenaux, Pierre
    Fruchtman, Steve
    Azarnia, Nozar
    Garcia-Manero, Guillermo
    BLOOD, 2015, 126 (23)
  • [28] A Phase II Study Of The Combination Of Azacitidine and Lenalidomide In Patients (pts) With Higher Risk Myelodysplastic Syndromes (MDS)
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Daver, Naval
    Jabbour, Elias
    Jain, Nitin
    Cortes, Jorge E.
    Estrov, Zeev
    Borthakur, Gautam
    Dong, Xiao Q.
    Kumar, Veeral J.
    Kantarjian, Hagop M.
    BLOOD, 2013, 122 (21)
  • [29] Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors
    Fujiwara, Yutaka
    Yamamoto, Noboru
    Yamada, Yasuhide
    Yamada, Kazuhiko
    Otsuki, Tetsuya
    Kanazu, Shinichi
    Iwasa, Takashi
    Hardwick, James S.
    Tamura, Tomohide
    CANCER SCIENCE, 2009, 100 (09): : 1728 - 1734
  • [30] Final results of a phase I study of the histone deacetylase inhibitor vorinostat (suberoyanilide hydroxamic acid, SAHA), in patients with leukemia and myelodysplastic syndrome
    Garcia-Manero, G
    Yang, H
    Sanchez-Gonzalez, B
    Verstovsek, S
    Ferrajoli, A
    Keating, M
    Andreeff, M
    O'Brien, S
    Cortes, J
    Wierda, W
    Faderl, S
    Koller, C
    Davis, J
    Morris, G
    Issa, JP
    Frankel, SR
    Richon, V
    Fine, B
    Kantarjian, H
    BLOOD, 2005, 106 (11) : 785A - 785A
12345